Investigational Drug Information for Cebranopadol
✉ Email this page to a colleague
What is the development status for investigational drug Cebranopadol?
Cebranopadol is an investigational drug.
There have been 9 clinical trials for Cebranopadol.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 18th 2013.
The most common disease conditions in clinical trials are Chronic Pain, Substance-Related Disorders, and Peripheral Nervous System Diseases. The leading clinical trial sponsors are Tris Pharma, Inc., Grünenthal GmbH, and Forest Laboratories.
Summary for Cebranopadol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 191 |
| WIPO Patent Applications | 69 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 3 (2013-12-18) |
| Vendors | 51 |
Recent Clinical Trials for Cebranopadol
| Title | Sponsor | Phase |
|---|---|---|
| Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain. | Tris Pharma, Inc. | Phase 1 |
| Assessment of Abuse Potential of Cebranopadol in Humans | Tris Pharma, Inc. | Phase 1 |
| CORAL XT - Open-label Extension Trial of the CORAL Trial | Grünenthal GmbH | Phase 3 |
Clinical Trial Summary for Cebranopadol
Top disease conditions for Cebranopadol
Top clinical trial sponsors for Cebranopadol
US Patents for Cebranopadol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
